Anon Photo

Xinning Wang

Research Assistant Professor, Biomedical Engineering
Develops cancer therapies and molecular image probes for cancer diagnosis
Office: B44
Phone Number: (216) 983-3254

Awards and Recognitions

2014, First Place Poster, World Molecular Imaging Conference

Research Interests

molecular image and molecular therapy

Professional Leadership and Service

Thursday, January 1, 2015 - PRESENT, Member World Molecular Imaging Society
Wednesday, January 1, 2003 - PRESENT, Member American Association of Cancer Research

Patents Received

2000, "Synthesis of Platinum Complexes and Uses Thereof," 6,110,907, Xinning Wang, Steven Au-Yeung, Yee-ping Ho, Ge Lin, Xiuwen Han, Shiwei Lu, Tao Jiang.

Patents Pending

2015, "PSMA-targeting imaging agents. ," 14/605124, Xinning Wang, Steve Huang, Warren Heston.
2014, "PSMA Targeted Ligands for Imaging and Therapy," US2014/016932, Xinning Wang, James Basilion, Clemens Burda.
2004, "Demethylcantharidin Platinum Complexes and Uses Thereof. ," 11/578, 002, Xinning Wang, Yee-ping Ho, Steven Au-Yeung, Kenneth To.


Walker, E., Turaga, S., Wang, X., Ramamurthy, G., Shukla, S., Basilion, J., ... Lathia, J. (2021). Development of Near-Infrared Imaging Agents for Detection of Junction Adhesion-Molecule A Protein. . Translational Oncology, 14 (3), 101007.
Wang, Y., De Leon, A., Perera, R., Abenojar, E., Ramamurthy, G., Basilion, J., ... Exner, A. (2021). Molecular Imaging of Orthotopic Prostate Cancer with Nanobubble Ultrasound Contrast Agents Targeted to PSMA. Scientific Reports, 11 (), 4726.
Johasen, M., Perera, R., Abenojar, E., Wang, X., Vincent, J., Exner, A., ... Brady-Kalnay, S. (2021). Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents. Int. J. Mol. Sci., 22 (4), 1983.
Wang, X., Senapati, S., Akinbote, A., Gnanasambandam, B., Park, P., & Senyo, S. (2020). Microenvironment stiffness requires decellularized cardiac extracellular matrix to promote heart regeneration in the neonatal mouse heart.. Acta biomaterialia, 113 (), 380-392.
Luo, D., Johnson, A., Wang, X., Zhao, J., Erokwu, B., Springer, S., ... Basilion, J. (2020). Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer.. Nano Letters, 20 (10), 7159-7167.
Perera, R., De Leon, A., Wang, X., Wang, Y., Ramamurthy, G., Peiris, P., ... Exner, A. (2020). Real Time Ultrasound Molecular Imaging of Prostate Cancer with PSMA-targeted Nanobubbles.. Nanomedicine: Nanotechnology, Biology and Medicine, 28 (), 102213.
Mulvihill, M., Luo, R., Estill, J., Liu, Y., Prentiss, M., Wang, J., ... On Behalf Of The Covid-Evidence And Recommendations Working Group (2020). Coronavirus disease (COVID-19): a scoping review.. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 25 (15).
Wang, X. (2019). Photodynamic Therapy as An Effective Adjuvant After Surgical Removal of Prostate Cancer . Cancer Research, ().
Luo, D., Wang, X., Zeng, S., Gopalakrishnan, R., Burda, C., & Basilion, J. (2019). Prostate-specific Membrane Antigen Targeted Gold Nanoparticles for Prostate Cancer Radiotherapy: Does Size Matter for Targeted Particles?" . Chem. Sci, ().
Luo, D., Wang, X., Zeng, S., Gopalakrishnan, R., Burda, C., & Basilion, J. (2019). Targeted Gold Nanocluster-enhanced Radiotherapy of Prostate Cancer. . SMALL, ().
Wang, X., Mangadlao, J., Escamillia, M., McCleese, C., Ramamurthy, G., Wang, Z., ... Basilion, J. (2018). Prostate Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer. ACS Nano, 12 (4), 3714-3725.
Wang, X., Tsui, B., Ramamurthy, G., Zhang, P., Meyers, J., Kenney, M., ... Basilion, J. (2016). Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.. Molecular cancer therapeutics, 15 (8), 1834-44.
Meyers, J., Cheng, Y., Broome, A., Agnes, R., Schluchter, M., Margevicius, S., ... Basilion, J. (2015). Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer.. Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems, 32 (4), 448-457.
Gillespie, D., Aguirre, M., Ravichandran, S., Leishman, L., Berrondo, C., Gamboa, J., ... Jensen, R. (2015). RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.. Journal of neurosurgery, 122 (2), 331-41.
Wang, X., Huang, S., Heston, W., Guo, Z., Wang, H., & Basilion, J. (2014). Development of targeted near-infrared imaging agents for prostate cancer.. Molecular cancer therapeutics, 13 (11), 2595-606.
Huang, S., Wang, X., Zhang, Y., Doke, A., DiFilippo, F., & Heston, W. (2014). Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.. The Prostate, 74 (7), 702-13.
Laydner, H., Huang, S., Heston, W., Autorino, R., Wang, X., Harsch, K., ... Feinstein, E. (2013). Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.. Urology, 81 (2), 451-6.
Wang, X., Tian, H., Lee, Z., & Heston, W. (2012). Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.. Nucleosides, nucleotides & nucleic acids, 31 (5), 432-44.
Wang, X., Mahanta, N., Olson, W., & Heston, W. (2011). In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.. Molecular cancer therapeutics, 10 (9), 1728-39.
Wang, X., Sayin, I., Rao, P., Feinstein, E., Harsch, K., Lee, Z., ... Heston, W. (2007). Targeted treatment of prostate cancer.. Journal of cellular biochemistry, 102 (3), 571-9.
Durso, R., Andjelic, S., Gardner, J., Margitich, D., Donovan, G., Arrigale, R., ... Olson, W. (2007). A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.. Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (13), 3999-4008.
Wang, X., Au-Yeung, S., & Ho, Y. (2007). Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.. Journal of inorganic biochemistry, 101 (6), 909-17.
Cramer, H., Okicki, J., Rhoads, K. R., Wang, X., Silverman, E., & Heston, W. (2007). 2-5A ligands--a new concept for the treatment of prostate cancer.. Nucleosides, nucleotides & nucleic acids, 26 (10-12), 1471-7.
Jayaprakash, S., Wang, X., Heston, W., & Kozikowski, A. (2006). Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy.. ChemMedChem, 1 (3), 299-302.
Ghosh, A., Wang, X., Klein, M., & Heston, W. (2005). Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.. Cancer research, 65 (3), 727-31.
Daltorio, K., Wang, X., Yu, R., Ho, Y., & Au-Yeung, S. (2004). Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin.. Bioorganic & medicinal chemistry, 12 (17), 4565-73.
Ho, Y., Daltorio, K., Au-Yeung, S., Wang, X., Lin, G., & Han, X. (2001). Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.. Journal of medicinal chemistry, 44 (13), 2065-8.